Why did Intellia Therapeutics rise on 5 October?
Written after the close on
Intellia Therapeutics +4.00%
Intellia Therapeutics, Inc. (NTLA on Nasdaq) rose very sharply over the last five trading days, outpacing a clearly higher S&P 500 and moving against a clearly lower healthcare sector, with the bulk of the gain coming in the latest session. An officer's plan to sell shares after exercising options is routine housekeeping and unlikely to explain the rise. Watch the early-November earnings report for updates on that trial and the company's pipeline.
Next report: · Add to calendar · Google Calendar
Open Intellia Therapeutics's chart
Earlier weeks
Intellia Therapeutics rose slightly as ARK bought shares. Over the last five trading days Intellia Therapeutics, Inc. (NTLA on Nasdaq) rose clearly, moving against a sharply weaker healthcare sector while the broad market was roughly flat. The gain looks tied to a regulatory boost: its lead CRISPR therapy — a gene-editing treatment that rewrites DNA to switch off a disease-causing gene — won priority review of its Biologics License Application, the formal US marketing application, which shortens the FDA's review clock. The latest session's small rise came alongside that ARK purchase, while chatter about an AI model unsettling gene-editing names partly capped the sector. Watch the early-November earnings report next.
Intellia holds steady as ARK buys and FDA review nears. Over the last five trading days Intellia was roughly unchanged, holding up better than a healthcare sector that fell clearly and roughly in line with a slightly weaker broad market. The most likely support came from the FDA accepting its application for lonvo-z in hereditary angioedema and granting Priority Review, a faster review path, with no advisory committee planned, plus fresh buying by Cathie Wood's ARK. Short interest, the share of freely tradable stock borrowed and sold by investors betting on a fall, sits near 42%, which likely added volatility without deciding direction. Watch the early-November earnings report next.